Related Experiment Video
Updated: Aug 15, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Thrombotic Microangiopathy-Like Phenotype in Patients With Infection-Associated Disseminated Intravascular
Naoki Takezako1,2, Fumiyo Komatsu3, Goichi Honda4
1Department of Hematology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
None:
Despite disseminated intravascular coagulation (DIC) and thrombotic microangiopathy (TMA) sharing features of thrombocytopenia, organ dysfunction, and bleeding, the relationship between these two conditions remains unclear. We therefore conducted a post hoc analysis of post-marketing surveillance data from Japan to evaluate the clinical characteristics of 2362 patients with DIC (TMA-like phenotype DIC, n = 217; and non-TMA-like phenotype DIC, n = 2145) who received thrombomodulin alfa (TM-α). TMA-like phenotype DIC was defined as platelet count < 15 × 104/μL, hemoglobin < 10 g/dL and lactate dehydrogenase > 500 IU/L. Approximately 9% of the registered infection-associated cases of DIC were TMA-like phenotype DIC. Patients with TMA-like phenotype were younger and had more renal dysfunction and liver dysfunction than those with non-TMA-like phenotype. Regarding the hemostatic examinations, fibrin/fibrinogen degradation products, D-dimer, and thrombin-antithrombin complex levels were higher in patients with TMA-like phenotype than in those with non-TMA-like phenotype. Patients with TMA-like phenotype had worse resolution of DIC and 28-day survival rates than those with non-TMA-like phenotype; however, the coagulation and fibrinolysis parameters in both groups showed improvement after TM-α administration. These findings describe a clinically severe subgroup of infection-associated DIC and should be interpreted as exploratory given that confirmatory TMA testing was unavailable.
More Related Videos
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins

